Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits. We analyzed the impact of GLP-1RA on cardiovascular and renal outcomes in patients with or without T2DM, with subgroup analysis based on sex, estimated glomerular filtration rate (eGFR), body mass index (BMI), and history of cardiovascular disease (CVD). A comprehensive database search for placebo-controlled RCTs on GLP-1RA treatment was conducted until April 2024. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with log odds ratios and 95% confidence intervals (CIs). A total of 13 CVOTs comprising 83,258 patients were included. GLP-1RAs significantly reduced MACE (OR 0.86, 95% CI: 0.80 to 0.94, p<0.01) all-cause mortality OR 0.87, 95% CI: 0.82 to 0.93, p<0.001, CV mortality (OR 0.87, 95% CI: 0.81 to 0.94, p<0.001), stroke (fatal: OR 0.74, 95% CI: 0.56 to 0.96, p=0.03; non-fatal: OR 0.87, 95% CI: 0.79 to 0.96, p=0.005), coronary revascularization (OR 0.86, 95% CI: 0.74 to 0.99, p=0.023), and composite kidney outcome (OR 0.76, 95% CI: 0.67 to 0.85, p<0.001. GLP-1RA significantly reduced MACE in both sexes. Furthermore, GLP-1RA reduced MACE regardless of CVD history, BMI, and eGFR level. Significant reductions in MACE, overall and CV mortality, stroke, coronary revascularization, and composite kidney outcome with GLP-1RA treatment were noted across all subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“However, on closer inspection, the significant heterogeneity of our result may be because only Lincoff, et al. (2023) and Marso (2016) had significant results.”
Background2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166 · cited 1×
“Both the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) recommend (class I, level of evidence A) the use of GLP-1RAs for patients with T2DM and chronic coronary syndrome/disease (CCS/CCD) in order to reduce MACE [38,39].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485 · cited 2×
“…damage to reduce future CVD and total mortality, and both should be considered (class IIa, level of evidence B) for patients with T2DM without ASCVD, HF, or CKD based on estimated future risks (e.g. using the ADVANCE risk score or DIAL model) for adverse cardiovascular or cardiorenal outcomes [43].”
BackgroundResultInfluential2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333 · cited 1×
“…of GLP-1RAs for patients with STEMI and NSTE-ACS, the newly published 2023 ESC guidelines for the management of ACS mentioned that SGLT2 inhibitors (SGLT2i) and GLP-1RAs reduce the risk of new ACS events, HF, and renal impairment, and the reduction is independent of baseline HbA1c levels [40].”
BackgroundThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Cited by
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Inceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Shekouh, D., Behboodi, M., Varmazyar, M., Khodadadiyan, A., Jochin, P., & Bazrafshan drissi, H. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08500-z · Cited by 1
Metadata
- Authors
- Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M.
- Venue
- American Journal of Preventive Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 18
- Pages
- 100679
- ISSN
- 2666-6677 (ISSN-L)
- OpenAlex
- W4396691213
- Cited by
- 155
- References
- 31
- FWCI
- 14.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. https://app.cochat.ai/papers/10.1016/j.ajpc.2024.100679
- The paper
- Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M. (2024). Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. American Journal of Preventive Cardiology. https://doi.org/10.1016/j.ajpc.2024.100679
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.